OTCMKTS:TRLPF Acerus Pharmaceuticals (TRLPF) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 07/21/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acerus Pharmaceuticals Stock (OTCMKTS:TRLPF) Get Acerus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.08▼$0.34VolumeN/AAverage Volume5,474 shsMarket Capitalization$56.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on developing and commercializing hormone-based therapies for men’s and women’s health. The company’s research and development programs target areas such as testosterone replacement, women’s health, and urology, with an emphasis on long-acting formulations and novel delivery systems. The company’s lead marketed product is AVEED, a long-acting injectable testosterone undecanoate formulation approved by the U.S. Food and Drug Administration and Health Canada for testosterone replacement therapy in adult men with primary hypogonadism or hypogonadotropic hypogonadism. In addition, Acerus offers Tefina, a subcutaneous norethindrone implant for endometriosis, and maintains a pipeline of early-stage candidates aimed at women’s reproductive health and other hormonal disorders. Acerus Pharmaceuticals operates primarily in North America, with commercial activities in the United States and Canada. The company also pursues strategic licensing and distribution partnerships to extend its products into European and other international markets. Manufacturing and quality control functions are managed through contract development and manufacturing organizations (CDMOs) that meet regulatory standards in multiple jurisdictions. Founded under a different corporate name and rebranded as Acerus in 2010, the company is led by President and Chief Executive Officer Greg Heil, whose leadership team brings experience in pharmaceutical R&D, regulatory affairs and commercialization. Acerus continues to invest in its pipeline and partnerships to address unmet needs in hormone therapy and specialty care.AI Generated. May Contain Errors. Read More Receive TRLPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRLPF Stock News HeadlinesTakeda Pharmaceutical Co. Ltd. ADRFebruary 8, 2024 | wsj.com2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To BenefitJanuary 1, 2023 | seekingalpha.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.October 23 at 2:00 AM | Banyan Hill Publishing (Ad)Acerus Reports Second Quarter 2022 Financial ResultsAugust 9, 2022 | financialpost.comFAcerus Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 15, 2022 | financialpost.comFSee More Headlines TRLPF Stock Analysis - Frequently Asked Questions How have TRLPF shares performed this year? Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of 2025. Since then, TRLPF shares have increased by 0.0% and is now trading at $0.22. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) posted its earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The specialty pharmaceutical company had revenue of $1.58 million for the quarter. Acerus Pharmaceuticals had a negative net margin of 254.66% and a negative trailing twelve-month return on equity of 346.72%. How do I buy shares of Acerus Pharmaceuticals? Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/05/2018Today10/23/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:TRLPF CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees29Year Founded2008Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.79 million Net Margins-254.66% Pretax MarginN/A Return on Equity-346.72% Return on Assets-94.54% Debt Debt-to-Equity Ratio0.64 Current Ratio1.35 Quick Ratio0.90 Sales & Book Value Annual Sales$7.38 million Price / Sales7.71 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares258,615,000Free FloatN/AMarket Cap$56.90 million OptionableNot Optionable Beta2.60 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (OTCMKTS:TRLPF) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acerus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.